MYLAN ApS: Financial statements 2024
CVR: 28107013
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
MYLAN ApS (CVR 28107013) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 3,631 and a net result of DKK 3,137 compared with DKK 1,952 the year before. That is an increase of 48.6% compared with the year before. Equity in the 2024 report amounted to DKK 198,978. The solvency ratio was 76.7%.
- Gross Profit
- DKK 3,631
- Profit/Loss
- DKK 3,137
- Equity
- DKK 198,978
- Total Assets
- DKK 259,360
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 4 t. | 3 t. | 199 t. | - |
| 2023 | - | 2 t. | 2 t. | 196 t. | - |
| 2022 | - | 2 t. | 50 | 194 t. | 0 |
| 2021 | - | 5 t. | 2 t. | 194 t. | 0 |
| 2020 | - | 5 t. | 2 t. | 192 t. | 0 |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
MYLAN ApS has published its annual report for 2023. Gross profit came to DKK 2,443, and the net result was DKK 1,952.
About MYLAN ApS
MYLAN ApS was a Danish company of the type Anpartsselskab based in Ballerup, founded in 2004. The company was registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named MERCK NM ApS and NM PHARMA ApS. In 2024, the company reported a gross profit of DKK 3,631 and a net result of DKK 3,137 compared with DKK 1,952 the year before. Equity in the 2024 report amounted to DKK 198,978.